查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1938401

全球抗過敏眼藥水市場－按藥物類別、類型、地區和競爭格局分類的產業規模、佔有率、趨勢、機會和預測（2021-2031年）

Allergy Relieving Eye Drops Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗過敏眼藥水市場預計將從 2025 年的 29.7 億美元成長到 2031 年的 40.7 億美元，複合年成長率為 5.39%。

這些眼科抗過敏藥物主要由抗組織胺藥物、肥大細胞穩定劑和非類固醇消炎劑（NSAIDs）組成，旨在緩解過敏性結膜炎引起的眼部症狀。市場成長的主要促進因素是全球過敏性疾病盛行率的上升，而這又歸因於環境污染加劇和氣候變遷導致的花粉季延長。此外，非處方藥的日益普及以及公眾對眼部健康管理重要性的認知不斷提高，也促進了市場擴張。

市場概覽
預測期 2027-2031
市場規模：2025年 29.7億美元
市場規模：2031年 40.7億美元
複合年成長率：2026-2031年 5.39%
成長最快的細分市場 抗組織胺藥物
最大的市場 北美洲

然而，由於長期使用可能產生的副作用，特別是防腐劑引起的眼部毒性，市場面臨巨大的挑戰，這可能會對患者的依從性產生負面影響。根據美國氣喘和過敏基金會預測，到2025年，美國每年將有超過1億人患有各種過敏症，證實了對有效治療方案的巨大而複雜的需求。因此，儘管干預需求很高，但市場必須在有效緩解症狀和長期用藥風險之間尋求平衡。

市場促進因素

全球過敏性結膜炎發生率的上升以及環境過敏原暴露的增加是推動全球抗過敏眼藥水市場發展的關鍵因素。氣候變遷顯著延長了花粉季，空氣中過敏原濃度的升高導致嚴重的眼部炎症，需要頻繁用藥。根據美國疾病管制與預防中心（CDC）的數據顯示，截至2025年3月，2024年的花粉濃度比歷史基準值高出20%，過敏季持續時間比往年延長約三週。這種環境變化導致越來越多的患者尋求緩解眼睛發癢、流淚等症狀，從而維持了對有效眼科解決方案的強勁需求。

同時，藥物傳遞技術和製劑研發的創新，特別是無防腐劑、長效眼藥水的研發，正在加速市場發展。製藥公司正利用這些趨勢來提高患者依從性並降低毒性風險。例如，2025年11月，愛爾康公司報告稱，其眼部健康業務的淨銷售額成長了7%，達到4.62億美元，這主要得益於其眼藥水產品線的強勁需求。這一收入成長反映了市場上過敏症狀日益嚴重的普遍性。 2025年3月，AccuWeather預測，美國39個州的某些地區的花粉濃度將超過歷史平均水平，這凸顯了可靠的過敏管理療法的迫切需求。

市場挑戰

全球抗過敏眼藥水市場面臨的主要障礙之一是長期使用的副作用，尤其是防腐劑引起的眼睛毒性。許多眼科抗過敏產品依賴苯扎氯銨等防腐劑來抑制微生物生長，但長期接觸這些物質會傷害眼表，導致刺痛、灼熱和上皮損傷等症狀。這可能導致適得其反的情況：治療反而加劇眼部不適，刺激症狀會模擬或加重過敏症狀，導致患者過早停止治療，從而降低處方續購率，並影響收入潛力。

近期行業數據證實了安全顧慮與患者猶豫之間的關聯。 2024年，視覺與眼科研究協會（ARVO）報告稱，公眾對眼科溶液安全性的關注度顯著提升，不利事件報道出現後，有關滴眼液安全性的在線搜尋增加了約93%。消費者擔憂的突然增加表明，毒性風險已成為藥物依從性的主要障礙。隨著患者對潛在的醫源性副作用越來越謹慎，市場難以將高發生率的眼部過敏轉化為持續的產品使用，導致整體成長緩慢。

市場趨勢

處方藥轉非處方藥（OTC）策略的加速推進正在從根本上改變市場動態。為了規避支付方監管並滿足過敏患者自行治療的需求，製造商正將現有的處方藥配方重新歸類為非處方藥，從而延長產品生命週期，並滿足消費者在無需臨床干預的情況下即時緩解症狀的需求。這項策略轉變已初見成效，樂敦製藥於2025年5月公佈的截至2025年3月31日的合併會計便印證了這一點。該公司淨銷售額成長14.0%，達到3,086.25億日圓，這一成長主要歸功於消費者保健和眼科護理產品的持續強勁表現。

同時，直接面對消費者（DTC）的電子商務管道的擴張已成為一大趨勢，品牌所有者正利用數位平台來確保持續收入並提升病人參與。這種演變超越了簡單的線上零售，融入了提供訂閱服務和個人化慢性過敏管理追蹤的先進系統，有效降低了對傳統藥房分銷的依賴。產業領軍企業正在證明這一模式的可行性。例如，博士倫在2025年2月發布的報告顯示，其2024年全年視力保健收入將達到27億美元，年增8%，凸顯了直接面對消費者的眼科健康策略日益成長的商業性成功。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球抗過敏眼藥水市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（抗組織胺、非類固醇消炎劑、血管收縮藥、其他）
    • 按類型（季節性/常年性過敏性結膜炎、春季角結膜炎、異位性角結膜炎、巨乳頭狀結膜炎、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美抗過敏眼藥水市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲抗過敏眼藥水市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區抗過敏眼藥水市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲抗過敏眼藥水市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲抗過敏眼藥水市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球抗過敏眼藥水市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc
  • Johnson & Johnson
  • Pfizer Inc
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Bausch Health Cos Inc
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19532

The Global Allergy Relieving Eye Drops Market is projected to expand from USD 2.97 Billion in 2025 to USD 4.07 Billion by 2031, registering a CAGR of 5.39%. These ophthalmic antiallergics, which include formulations based on antihistamines, mast cell stabilizers, or non-steroidal anti-inflammatory drugs (NSAIDs), are engineered to alleviate ocular symptoms linked to allergic conjunctivitis. Market growth is primarily fueled by the rising global prevalence of allergic conditions, driven by increasing environmental pollution and extended pollen seasons attributed to climate change. Furthermore, the expansion is supported by the greater accessibility of over-the-counter treatments and heightened public awareness regarding the importance of ocular health management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.97 Billion
Market Size 2031USD 4.07 Billion
CAGR 2026-20315.39%
Fastest Growing SegmentAntihistamines
Largest MarketNorth America

However, the market faces a significant hurdle regarding the potential for adverse effects from long-term usage, specifically ocular toxicity caused by preservatives, which can negatively impact patient adherence. The Asthma and Allergy Foundation of America notes that in 2025, over 100 million individuals in the United States suffer from various allergies annually, underscoring the vast yet complex demand for effective therapeutic solutions. Consequently, while the need for intervention is high, the market must navigate the balance between effective symptom relief and the risks associated with prolonged pharmacological exposure.

Market Driver

The primary forces propelling the Global Allergy Relieving Eye Drops Market are the increasing global incidence of allergic conjunctivitis combined with escalating exposure to environmental allergens. Climate change is noticeably intensifying pollen seasons, resulting in higher airborne allergen concentrations that cause severe ocular inflammation and necessitate frequent medication. According to the Centers for Disease Control and Prevention, pollen concentrations recorded in 2024 were 20% higher than historical baselines as of March 2025, with the allergy season persisting approximately three weeks longer than previously observed. This environmental shift has broadened the patient demographic seeking relief for symptoms like itching and tearing, thereby maintaining robust demand for effective ophthalmic solutions.

Simultaneously, the market is being accelerated by innovations in drug delivery and formulation, particularly the development of preservative-free and long-acting eye drops. Pharmaceutical entities are leveraging this trend to enhance patient compliance and reduce toxicity risks. For example, Alcon reported in November 2025 that its ocular health net sales rose by 7% to $462 million, fueled by strong demand for its eye drop portfolio. This revenue growth mirrors the wider market landscape where aggravated allergy conditions are becoming ubiquitous; AccuWeather forecast in March 2025 that pollen counts would exceed historical averages in parts of 39 states, highlighting the critical need for reliable allergy management therapies.

Market Challenge

A significant obstacle hindering the Global Allergy Relieving Eye Drops Market is the occurrence of adverse effects linked to prolonged usage, particularly preservative-induced ocular toxicity. Many ophthalmic antiallergic products rely on preservatives like benzalkonium chloride to inhibit microbial growth, yet chronic exposure to these substances can damage the ocular surface and induce symptoms such as stinging, burning, and epithelial injury. This creates a counterproductive scenario where the treatment aggravates ocular discomfort, leading patients to discontinue therapy prematurely when irritation mimics or worsens their allergic symptoms, which in turn limits repeat prescriptions and hampers revenue potential.

Recent industry data confirms a correlation between safety concerns and patient hesitation. The Association for Research in Vision and Ophthalmology (ARVO) reported in 2024 that public scrutiny regarding the safety of ophthalmic solutions surged, with online searches concerning eye drop safety rising by approximately 93% following reports of adverse events. This sharp increase in consumer apprehension demonstrates that toxicity risks serve as a major barrier to adherence. As patients exercise greater caution regarding potential iatrogenic effects, the market faces difficulty in converting the high prevalence of ocular allergies into sustained product usage, ultimately stalling overall expansion.

Market Trends

The acceleration of Rx-to-OTC switch strategies is fundamentally altering market dynamics as manufacturers aim to bypass payer restrictions and address the self-medication preferences of allergy sufferers. By reclassifying established prescription formulations as over-the-counter products, companies are extending product lifecycles and meeting consumer demand for immediate access to relief without clinical barriers. This strategic shift is generating substantial financial rewards, as demonstrated by Rohto Pharmaceutical in May 2025; their consolidated results for the fiscal year ending March 31, 2025, showed a 14.0% increase in net sales to 308,625 million yen, a rise largely credited to the sustained strength of their consumer healthcare and eye care lines.

In parallel, the expansion of Direct-to-Consumer E-Commerce channels is emerging as a critical trend, with brand owners utilizing digital platforms to secure recurring revenue and improve patient engagement. This evolution transcends simple online retail by incorporating sophisticated systems that offer subscription services and personalized tracking for chronic allergy management, effectively reducing reliance on traditional pharmacy distribution. Major industry players are proving the viability of this model; Bausch + Lomb reported in February 2025 that their Vision Care segment revenue hit $2.7 billion for the full year 2024, an 8% increase that highlights the growing commercial success of consumer-facing eye health strategies.

Key Market Players

  • AbbVie Inc
  • Johnson & Johnson
  • Pfizer Inc
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Bausch Health Cos Inc
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co Ltd

Report Scope

In this report, the Global Allergy Relieving Eye Drops Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Relieving Eye Drops Market, By Drug Class

  • Antihistamines
  • Non-steroidal anti-Inflammatory Drugs
  • Vasoconstrictors
  • Others

Allergy Relieving Eye Drops Market, By Type

  • Seasonal and Perennial Allergic Conjunctivitis
  • Vernal Keratoconjunctivitis
  • Atopic Keratoconjunctivitis
  • Giant Papillary Conjunctivitis
  • Others

Allergy Relieving Eye Drops Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Relieving Eye Drops Market.

Available Customizations:

Global Allergy Relieving Eye Drops Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Relieving Eye Drops Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Antihistamines, Non-steroidal anti-Inflammatory Drugs, Vasoconstrictors, Others)
    • 5.2.2. By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Giant Papillary Conjunctivitis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Allergy Relieving Eye Drops Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Allergy Relieving Eye Drops Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
    • 6.3.2. Canada Allergy Relieving Eye Drops Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
    • 6.3.3. Mexico Allergy Relieving Eye Drops Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type

7. Europe Allergy Relieving Eye Drops Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Allergy Relieving Eye Drops Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
    • 7.3.2. France Allergy Relieving Eye Drops Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Allergy Relieving Eye Drops Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Allergy Relieving Eye Drops Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Allergy Relieving Eye Drops Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type

8. Asia Pacific Allergy Relieving Eye Drops Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Allergy Relieving Eye Drops Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
    • 8.3.2. India Allergy Relieving Eye Drops Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
    • 8.3.3. Japan Allergy Relieving Eye Drops Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
    • 8.3.4. South Korea Allergy Relieving Eye Drops Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Allergy Relieving Eye Drops Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type

9. Middle East & Africa Allergy Relieving Eye Drops Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Allergy Relieving Eye Drops Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
    • 9.3.2. UAE Allergy Relieving Eye Drops Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
    • 9.3.3. South Africa Allergy Relieving Eye Drops Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type

10. South America Allergy Relieving Eye Drops Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Allergy Relieving Eye Drops Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
    • 10.3.2. Colombia Allergy Relieving Eye Drops Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
    • 10.3.3. Argentina Allergy Relieving Eye Drops Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Allergy Relieving Eye Drops Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson
  • 15.3. Pfizer Inc
  • 15.4. F Hoffmann-La Roche AG
  • 15.5. Novartis AG
  • 15.6. Bausch Health Cos Inc
  • 15.7. Regeneron Pharmaceuticals Inc
  • 15.8. Santen Pharmaceutical Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer